Maynard Um
-
-
-
-
-
-
-
CASTLE Biosciences' Barrett's esophagus test reaches 100,000 orders
-
-
-
-
-
-
-
Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 24c
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)
-
-
-
-
-
-
-
Castle Biosciences receives FDA breakthrough designation for melanoma test
-
-
-
-
-
-
-
Castle Biosciences Inc. (CSTL) Misses Q1 EPS by 14c
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL), 'remain highly bullish'
-
-
-
-
-
-
-
Castle Biosciences (CSTL) PT Raised to $40 at BTIG
-
466,315 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


